Apr. 8 at 12:46 PM
$OTLK In early 2026, an agreement was reached with German health insurance providers and the NHS in the UK, meaning sales in Europe can now begin.
There is also hope that the FDA will either withdraw its objection to the non-approval or issue a clear statement outlining the requirements for Lytenava’s approval. After all, the drug has been used successfully for many years.
At present, the prospects are clearly favourable, particularly given a market capitalisation of less than
$30 million.
